Drug/Small Molecule:
rifampin

PharmGKB contains no dosing guidelines for this drug/small molecule. To report known genotype-based dosing guidelines, or if you are interested in developing guidelines, click here.

PharmGKB annotates drug labels containing pharmacogenetic information approved by the US Food and Drug Administration (FDA), European Medicines Agency (EMA) and the Pharmaceuticals and Medical Devices Agency, Japan (PMDA). PharmGKB annotations provide a brief summary of the PGx in the label, an excerpt from the label and a downloadable highlighted label PDF file. A list of genes and phenotypes found within the label is mapped to label section headers and listed at the end of each annotation. PharmGKB also attempts to interpret the level of action implied in each label with the "PGx Level" tag.

Sources:

  • FDA Information is gathered from the FDA's "Table of Pharmacogenomic Biomarkers in Drug Labels" and from FDA-approved labels brought to our attention. Please note that drugs may be removed from or added to the FDA's Table without our knowledge. We periodically check the Table for changes and update PharmGKB accordingly. Drugs listed on the Table to our knowledge are tagged with the Biomarker icon. A drug label that has been removed from the Table will not have the Biomarker icon but will continue to have an annotation on PharmGKB stating the label has been removed from the FDA's Table. We acquire label PDF files from DailyMed.
  • EMA European Public Assessment Reports (EPARs) that contain PGx information were identified from [Article:24433361] and also by searching for drugs for which we have PGx-containing FDA drug labels.

We welcome any information regarding drug labels containing PGx information approved by the FDA, EMA, PMDA or other Medicine Agencies around the world - please contact feedback.


last updated 10/25/2013

FDA Label for isoniazid, pyrazinamide, rifampin and NAT2

Informative PGx

Summary

'Slow inactivators' of isoniazid may be more susceptible to drug toxicity when taking Rifator due to higher blood concentrations of the drug in these individuals. Acetylation status of an individual can be determined by examining genetic variants in the NAT2 gene.

Annotation

NAT1 and NAT2 genes are biomarkers listed for the Rifampin, Isoniazid and Pyrazinamide (Rifator) drug label in the FDA Table of Pharmacogenomic Biomarkers in Drug Labels table, however the latest available drug label for Rifator (updated on 27/02/2013) does not specifically mention genetic or biomarker testing for these genes. The label does contain information relating to the metabolism of isoniazid by acetylation and dehydrazination. NAT1 and NAT2 are acetyltransferase enzymes. The label states that slow acetylators may have higher blood levels of isoniazid. Acetylation status of an individual can be determined by examining genetic variants in the NAT2 gene (see NAT2 VIP summary).

The label also mentions that Rifampin and Isoniazid can induce or inhibit particular CYP450 enzymes, and therefore could affect the metabolism of drugs taken concomitantly that are metabolized via these enzymes.

Excerpts from the Rifampin, Isoniazid, Pyrazinamid (RIFATER) drug label:

The rate of acetylation does not significantly alter the effectiveness of isoniazid. However, slow acetylation may lead to higher blood levels of the drug, and thus, an increase in toxic reactions.

For the complete drug label text with sections containing pharmacogenetic information highlighted, see the Rifampin, Isoniazid and Pyrazinamide drug label.

*Disclaimer: The contents of this page have not been endorsed by the FDA and are the sole responsibility of PharmGKB.

Genes and/or phenotypes found in this label

  • Hepatitis, Toxic
    • Indications & usage section, Contraindications section, Warnings section, Precautions section
    • source: PHONT
  • HIV
    • Indications & usage section
    • source: PHONT
  • Leukemia
    • Indications & usage section, Precautions section
    • source: PHONT
  • Toxic liver disease
    • Adverse reactions section, Precautions section
    • source: PHONT
  • Tuberculosis
    • Indications & usage section, Warnings section, Precautions section
    • source: PHONT

PharmGKB contains no Clinical Variants that meet the highest level of criteria.

To see more Clinical Variants with lower levels of criteria, click the button at the bottom of the page.

Disclaimer: The PharmGKB's clinical annotations reflect expert consensus based on clinical evidence and peer-reviewed literature available at the time they are written and are intended only to assist clinicians in decision-making and to identify questions for further research. New evidence may have emerged since the time an annotation was submitted to the PharmGKB. The annotations are limited in scope and are not applicable to interventions or diseases that are not specifically identified.

The annotations do not account for individual variations among patients, and cannot be considered inclusive of all proper methods of care or exclusive of other treatments. It remains the responsibility of the health-care provider to determine the best course of treatment for a patient. Adherence to any guideline is voluntary, with the ultimate determination regarding its application to be made solely by the clinician and the patient. PharmGKB assumes no responsibility for any injury or damage to persons or property arising out of or related to any use of the PharmGKB clinical annotations, or for any errors or omissions.

? = Mouse-over for quick help

This is a non-comprehensive list of genetic tests with pharmacogenetics relevance, typically submitted by the manufacturer and manually curated by PharmGKB. The information listed is provided for educational purposes only and does not constitute an endorsement of any listed test or manufacturer.

A more complete listing of genetic tests is found at the Genetic Testing Registry (GTR).

PGx Test Variants Assayed Gene?

The table below contains information about pharmacogenomic variants on PharmGKB. Please follow the link in the "Variant" column for more information about a particular variant. Each link in the "Variant" column leads to the corresponding PharmGKB Variant Page. The Variant Page contains summary data, including PharmGKB manually curated information about variant-drug pairs based on individual PubMed publications. The PMIDs for these PubMed publications can be found on the Variant Page.

The tags in the first column of the table indicate what type of information can be found on the corresponding Variant Page.

Links in the "Gene" column lead to PharmGKB Gene Pages.

List of all rifampin variant annotations

Gene ? Variant?
(142)
Alternate Names ? Drugs ? Alleles ?
(+ chr strand)
Function ? Amino Acid?
Translation
No VIP available No VIP available VA CYP2B6 *1 N/A N/A N/A
No VIP available No VIP available VA CYP2E1 *5B N/A N/A N/A
No VIP available No VIP available VA CYP2E1 *6 N/A N/A N/A
No VIP available CA No VIP available GSTM1 non-null N/A N/A N/A
No VIP available CA VA GSTM1 null N/A N/A N/A
No VIP available CA No VIP available GSTT1 non-null N/A N/A N/A
No VIP available CA VA GSTT1 null N/A N/A N/A
No VIP available No VIP available VA NAT2 *4 N/A N/A N/A
No VIP available No VIP available VA NAT2 *5 N/A N/A N/A
No VIP available No VIP available VA NAT2 *5A N/A N/A N/A
No VIP available No VIP available VA NAT2 *5B N/A N/A N/A
No VIP available No VIP available VA NAT2 *5D N/A N/A N/A
No VIP available No VIP available VA NAT2 *6 N/A N/A N/A
No VIP available No VIP available VA NAT2 *6A N/A N/A N/A
No VIP available No VIP available VA NAT2 *6B N/A N/A N/A
No VIP available No VIP available VA NAT2 *7 N/A N/A N/A
No VIP available No VIP available VA NAT2 *7A N/A N/A N/A
No VIP available No VIP available VA NAT2 *7B N/A N/A N/A
No VIP available No VIP available VA NAT2 *14 N/A N/A N/A
No VIP available No Clinical Annotations available VA
rs1041983 14041C>T, 18257795C>T, 282C>T, 6115941C>T, NAT2:282C>T, Tyr94=, signature SNP for NAT2*13 allelic group
C > T
Synonymous
Tyr94Tyr
No VIP available No Clinical Annotations available VA
rs1045642 208920T>A, 208920T>C, 25171488A>G, 25171488A>T, 3435T>A, 3435T>C, 87138645A>G, 87138645A>T, ABCB1*6, ABCB1: 3435C>T, ABCB1: C3435T, ABCB1: c.3435C>T, ABCB1:3435C>T, Ile1145=, Ile1145Ile, MDR1 3435C>T, MDR1 C3435T, PGP C3435T, c.3435C>T, mRNA 3853C>T
A > T
A > G
Synonymous
Ile1145Ile
No VIP available No Clinical Annotations available VA
rs1057910 1075A>C, 47545517A>C, 47639A>C, 96741053A>C, CYP2C9*3, CYP2C9*3:Ile359Leu, CYP2C9: I359L, CYP2C9:359Ile>Leu, CYP2C9:Ile359Leu, Ile359Leu, mRNA 11A>C
A > C
Missense
Ile359Leu
No VIP available No Clinical Annotations available VA
rs1080983 -1775A>G, 21919137T>C, 3316A>G, 42528568T>C, CYP2D6(-1775)A>G
T > C
5' Flanking
No VIP available No Clinical Annotations available VA
rs1080989 -1000G>A, 21918362C>T, 4091G>A, 42527793C>T, CYP2D6(-1000)A>G
C > T
5' Flanking
No VIP available No Clinical Annotations available VA
rs11045819 14089937C>A, 21329813C>A, 463C>A, 50686C>A, Pro155Thr, SLCO1B1:*4, SLCO1B1:463C>A
C > A
Missense
Pro155Thr
No VIP available CA VA
rs11080344 1281+1205A>G, 26104511T>C, 28045A>G, 841505T>C
T > C
Intronic
No VIP available No Clinical Annotations available VA
rs11125883 2678-347T>G, 40532460A>C, 61710573A>C
A > C
Intronic
No VIP available No Clinical Annotations available VA
rs1799929 14240C>T, 18257994C>T, 481C>T, 6116140C>T, KpnI, Leu161=, NAT2*14C. T allele defines "M1", NAT2:481C>T, signature SNP for NAT2*11 allelic group
C > T
Synonymous
Leu161Leu
No VIP available No Clinical Annotations available VA
rs1799930 14349G>A, 18258103G>A, 590G>A, 6116249G>A, Arg197Gln, NAT2:590G>A, NAT2:ARG197GLN, alleles and*14D. A allele defines "M2", signature SNP for NAT2*6 allelic group
G > A
Missense
Arg197Gln
No VIP available No Clinical Annotations available VA
rs1799931 14616G>A, 18258370G>A, 6116516G>A, 857G>A, NAT2:857G>A, NAT2:GLY286GLU, NAT2:rs1799931 A>G, NM_000015.2:c.857G>A, NP_000006.2:p.Gly286Glu, included in NAT2*7B. A allele defines "M3", signature SNP for NAT2*7 allelic group
G > A
Missense
Gly286Glu
No VIP available No Clinical Annotations available VA
rs1800629 -308, -308G>A, -488G>A, 2828572G>A, 2836669G>A, 2873832G>A, 2885915G>A, 2922737G>A, 3052647A>A, 31483031G>A, 31543031G>A, 4682G>A, 8156G>A, TNF alpha -308G/A, TNF2, TNF:, TNF:-308 G/A, TNF:-308G/A
G > A
5' Flanking
No VIP available No Clinical Annotations available VA
rs1801280 14100T>C, 18257854T>C, 341T>C, 6116000T>C, Ile114Thr, NAT2:341T>C, NAT2:ILE114THR, signature SNP for NAT2*5 allelic group
T > C
Missense
Ile114Thr
No VIP available No Clinical Annotations available VA
rs2003569 -997G>A, 174548G>A, 234667937G>A, 61-7743G>A, 614196G>A, 856-7743G>A, 862-7743G>A, 868-7743G>A, UGT1A1(-997)G>A
G > A
Intronic
No VIP available No Clinical Annotations available VA
rs2008584 -758A>G, 143626A>G, 234637015A>G, 583274A>G, 60+34504A>G, 856-38665A>G, 861+34504A>G, 867+14511A>G, 867+8682A>G, UGT1A3(-758)A>G
A > G
Intronic
No VIP available No Clinical Annotations available VA
rs2031920 (-1053)C>T (Rsa 1 c1>c2), -1055C>T, 135339845C>T, 3979C>T, 6573776C>T, CYP2E1(-1055)C>T, Rsa1
C > T
5' Flanking
No VIP available No Clinical Annotations available VA
rs2070401 *331A>G, 16377356A>G, 1921-8470A>G, 30715485A>G, 49266A>G
A > G
Intronic
No VIP available No Clinical Annotations available VA
rs2070672 -352A>G, 135340548A>G, 4682A>G, 6574479A>G, CYP2E1(-352)A>G
A > G
5' Flanking
No VIP available No Clinical Annotations available VA
rs2070673 -333A>T, 135340567A>T, 4701A>T, 6574498A>T, CYP2E1(-333)A>T
A > T
5' Flanking
No VIP available No Clinical Annotations available VA
rs2306283 14089862A>G, 21329738A>G, 388A>G, 50611A>G, Asn130Asp, SLCO1B1*1B
A > G
Missense
Asn130Asp
No VIP available CA VA
rs2472677 -22-7659C>T, 119518417C>T, 24087C>T, 26013563C>T, 96-7659C>T, NR1I2:63396C>T, PXR 63396C>T
C > T
Intronic
No VIP available No Clinical Annotations available VA
rs3755319 -1352A>C, 174193A>C, 234667582A>C, 61-8098A>C, 613841A>C, 856-8098A>C, 862-8098A>C, 868-8098A>C, UGT1A1(-1352)A>C
A > C
Intronic
No VIP available No Clinical Annotations available VA
rs3813867 -1295G>C, 135339605G>C, 3739G>C, 6573536G>C, CYP2E1(-1295)C>G
G > C
5' Flanking
rs3814055 -1135C>T, -1570C>T, 119500035C>T, 25995181C>T, 5705C>T
C > T
5' Flanking
No VIP available No Clinical Annotations available VA
rs3814637 -1418C>G, -1418C>T, 3583C>G, 3583C>T, 47325509C>G, 47325509C>T, 96521045C>G, 96521045C>T
C > G
C > T
5' Flanking
No VIP available No Clinical Annotations available VA
rs4148323 175755G>A, 211G>A, 234669144G>A, 61-6536G>A, 615403G>A, 856-6536G>A, 862-6536G>A, 868-6536G>A, Gly71Arg, UGT1A1*6, UGT1A1: G71R, UGT1A1:211G>A, UGT1A1:G211A, UGT1A1:Gly71Arg
G > A
Intronic
Gly71Arg
No VIP available No Clinical Annotations available VA
rs4149032 14077915C>T, 21317791C>T, 38664C>T, 85-7793C>T
C > T
Intronic
No VIP available CA VA
rs4149056 14091673T>C, 21331549T>C, 521T>C, 52422T>C, SLCO1B1*5, Val174Ala
T > C
Missense
Val174Ala
No VIP available No Clinical Annotations available VA
rs4646244 -1144T>A, 18247718T>A, 3964T>A, 6105864T>A, NAT2(-9796)T>A
T > A
5' Flanking
No VIP available No Clinical Annotations available VA
rs4646267 -949A>G, 18247913A>G, 4159A>G, 6106059A>G, NAT2(-9601)A>G
A > G
5' Flanking
No VIP available No Clinical Annotations available VA
rs4720833 -45+3869A>G, 114T>C, 1564403A>G, 1574403A>G
A > G
Intronic
No VIP available No Clinical Annotations available VA
rs4918758 -1188T>C, 3838T>C, 47501716T>C, 96697252T>C, CYP2C9(-1158)C>T
T > C
5' Flanking
No VIP available No Clinical Annotations available VA
rs4986893 22948G>A, 47344874G>A, 636G>A, 96540410G>A, CYP2C19*3, CYP2C19:636G>A, CYP2C19:G636A, Trp212Ter
G > A
Stop Codon
Trp212null
No VIP available No Clinical Annotations available VA
rs6413432 12678T>A, 135348544T>A, 6582475T>A, 967+1143T>A, CYP2E1*6 (DraI RFLP, T7632A SNP, rs6413432)
T > A
Intronic
No VIP available No Clinical Annotations available VA
rs6431625 140T>C, 144523T>C, 234637912T>C, 584171T>C, 60+35401T>C, 856-37768T>C, 861+35401T>C, 867+15408T>C, 867+9579T>C, UGT1A3 V47A(T>C), Val47Ala
T > C
Intronic
Val47Ala
No VIP available No Clinical Annotations available VA
rs9332096 -1565C>T, 3461C>T, 47501339C>T, 96696875C>T, CYP2C9(-1565)C>T
C > T
5' Flanking
Alleles, Functions, and Amino Acid Translations are all sourced from dbSNP 142

Overview

Generic Names
  • RFP
  • rifampin
Trade Names
  • Archidyn
  • L-5103 Lepetit
  • R/AMP
  • RAMP
  • Rfamipicin
  • Rifa
  • Rifadin
  • Rifadin IV
  • Rifadine
  • Rifagen
  • Rifaldazin
  • Rifaldazine
  • Rifaldin
  • Rifampicin
  • Rifampicin SV
  • Rifamycin
  • Rifamycin Amp
  • Rifaprodin
  • Rifoldin
  • Rifoldine
  • Riforal
  • Rimactan
  • Rimactane
  • Rimactin
  • Rimazid
  • Rofact
  • Tubocin
Brand Mixture Names
  • Rifamate (Rifampin + Isoniazid)
  • Rifater (Isoniazid + Pyrazinaamide + Rifampin)

PharmGKB Accession Id:
PA451250

Description

A semisynthetic antibiotic produced from Streptomyces mediterranei. It has a broad antibacterial spectrum, including activity against several forms of Mycobacterium. In susceptible organisms it inhibits DNA-dependent RNA polymerase activity by forming a stable complex with the enzyme. It thus suppresses the initiation of RNA synthesis. Rifampin is bactericidal, and acts on both intracellular and extracellular organisms. (From Gilman et al., Goodman and Gilman's The Pharmacological Basis of Therapeutics, 9th ed, p1160)

Source: Drug Bank

Indication

For the treatment of Tuberculosis and Tuberculosis-related mycobacterial infections.

Source: Drug Bank

Other Vocabularies

Information pulled from DrugBank has not been reviewed by PharmGKB.

Pharmacology, Interactions, and Contraindications

Mechanism of Action

Rifampin acts via the inhibition of DNA-dependent RNA polymerase, leading to a suppression of RNA synthesis and cell death.

Source: Drug Bank

Pharmacology

Rifampin is an antibiotic that inhibits DNA-dependent RNA polymerase activity in susceptible cells. Specifically, it interacts with bacterial RNA polymerase but does not inhibit the mammalian enzyme. It is bactericidal and has a very broad spectrum of activity against most gram-positive and gram-negative organisms (including Pseudomonas aeruginosa) and specifically Mycobacterium tuberculosis. Because of rapid emergence of resistant bacteria, use is restricted to treatment of mycobacterial infections and a few other indications. Rifampin is well absorbed when taken orally and is distributed widely in body tissues and fluids, including the CSF. It is metabolized in the liver and eliminated in bile and, to a much lesser extent, in urine, but dose adjustments are unnecessary with renal insufficiency.

Source: Drug Bank

Food Interaction

Avoid alcohol.|Take on empty stomach: 1 hour before or 2 hours after meals.|Take with a full glass of water.

Source: Drug Bank

Absorption, Distribution, Metabolism, Elimination & Toxicity

Biotransformation

Primarily hepatic, rapidly deacetylated.

Source: Drug Bank

Protein Binding

89%

Source: Drug Bank

Absorption

Well absorbed from gastrointestinal tract.

Source: Drug Bank

Half-Life

3.35 (+/- 0.66) hours

Source: Drug Bank

Toxicity

LD 50=1570 mg/kg (rat), chronic exposure may cause nausea and vomiting and unconsciousness

Source: Drug Bank

Clearance

Source: Drug Bank

Route of Elimination

Less than 30% of the dose is excreted in the urine as rifampin or metabolites.

Source: Drug Bank

Chemical Properties

Chemical Formula

C43H58N4O12

Source: Drug Bank

Isomeric SMILES

Cc1c(c2c3c4c1O[C@@](C4=O)(OC=C[C@@H]([C@H]([C@H]([C@@H]([C@@H]([C@@H]([C@H]([C@H](C=CC=C(C(=O)Nc(c2O)c(c3O)C=NN5CCN(CC5)C)C)C)O)C)O)C)OC(=O)C)C)OC)C)O

Source: OpenEye

Canonical SMILES

CO[C@H]1\C=C\O[C@@]

Source: Drug Bank

Average Molecular Weight

822.9402

Source: Drug Bank

Monoisotopic Molecular Weight

822.40512334

Source: Drug Bank

PharmGKB Curated Pathways

Pathways created internally by PharmGKB based primarily on literature evidence.

  1. Etoposide Pathway, Pharmacokinetics/Pharmacodynamics
    Etoposide cellular disposition and effects.

External Pathways

Links to non-PharmGKB pathways.

PharmGKB contains no links to external pathways for this drug. To report a pathway, click here.

Genes that are associated with this drug in PharmGKB's database based on (1) variant annotations, (2) literature review, (3) pathways or (4) information automatically retrieved from DrugBank, depending on the "evidence" and "source" listed below.

Curated Information ?

Drug Targets

Gene Description
ABCB1 (source: Drug Bank)
NR1I2 (source: Drug Bank)

Curated Information ?

EvidenceDrug
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available No VIP available No VIP available
efavirenz
EvidenceDrug Class
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available No VIP available No VIP available
vitamin d and analogues

Drug Interactions

Drug Description
rifampin Rifampin decreases the effect of sulfonylurea (source: Drug Bank)
rifampin Rifampin decreases the effect of theophylline (source: Drug Bank)
rifampin Rifampin decreases the effect of amiodarone (source: Drug Bank)
rifampin Rifampin decreases the effect of amiodarone (source: Drug Bank)
rifampin The rifamycin decreases the effect of tricyclics (source: Drug Bank)
rifampin The rifamycin, rifampin, may decrease the effect of the tricyclic antidepressant, amitriptyline, by increasing its metabolism. Monitor for changes in the therapeutic and adverse effects of amitriptyline if rifampin is initiated, discontinued or dose changed. (source: Drug Bank)
rifampin The rifamycin decreases the effect of tricyclics (source: Drug Bank)
rifampin The rifamycin, rifampin, may decrease the effect of the tricyclic antidepressant, amoxapine, by increasing its metabolism. Monitor for changes in the therapeutic and adverse effects of amoxapine if rifampin is initiated, discontinued or dose changed. (source: Drug Bank)
rifampin In presence of rifampin anticipate decrease of amprenavir efficiency (source: Drug Bank)
rifampin In presence of rifampin anticipate decrease of amprenavir efficiency (source: Drug Bank)
rifampin The CYP3A4 inducer, rifampin, may decrease the effect of aprepitant. (source: Drug Bank)
rifampin Rifampin reduces levels and efficacy of atazanavir (source: Drug Bank)
rifampin Rifampin reduces levels and efficacy of atazanavir (source: Drug Bank)
rifampin The rifamycin decreases the effect of the statin drug (source: Drug Bank)
rifampin The rifamycin decreases the effect of the statin drug (source: Drug Bank)
rifampin The agent decreases the effect of atovaquone (source: Drug Bank)
rifampin Rifampin may decrease the effect of atovaquone. (source: Drug Bank)
rifampin The enzyme inducer, rifampin, may decrease the effect of the corticosteroid, betamethasone. (source: Drug Bank)
rifampin Rifampin decreases the effect of the metabolized beta-blocker (source: Drug Bank)
rifampin Rifampin may decrease the serum concentration of bisopolol by increasing its metabolism. (source: Drug Bank)
rifampin Rifampin may decrease the serum concentration of bromazepam by increasing its metabolism. Monitor for changes in the therapeutic and adverse effects of bromazepam if rifampin is initiated, discontinued or dose changed. (source: Drug Bank)
rifampin Rifampin reduces bupropion levels (source: Drug Bank)
rifampin Rifampin reduces bupropion levels (source: Drug Bank)
rifampin Rifampin decreases the effect of buspirone (source: Drug Bank)
rifampin Rifampin decreases the effect of buspirone (source: Drug Bank)
rifampin Decreased levels/effect of the NSAID (source: Drug Bank)
rifampin Rifampin, a CYP2C9 inducer, may increase the metabolism of celecoxib. (source: Drug Bank)
rifampin The rifamycin decreases the effect of statin drug (source: Drug Bank)
rifampin The rifamycin decreases the effect of statin drug (source: Drug Bank)
rifampin Rifampin decreases the effect of chloramphenicol (source: Drug Bank)
rifampin Rifampin decreases the effect of chloramphenicol (source: Drug Bank)
rifampin Rifampin decreases the effect of sulfonylurea (source: Drug Bank)
rifampin Rifampin decreases the effect of sulfonylurea (source: Drug Bank)
rifampin The rifamycin decreases the effect of the macrolide (source: Drug Bank)
rifampin The rifamycin, rifampin, may decrease the effect of the macrolide, clarithromycin. (source: Drug Bank)
rifampin The rifamycin decreases the effect of tricyclics (source: Drug Bank)
rifampin The rifamycin, rifampin, may decrease the effect of the tricyclic antidepressant, clomipramine, by increasing its metabolism. Monitor for changes in the therapeutic and adverse effects of clomipramine if rifampin is initiated, discontinued or dose changed. (source: Drug Bank)
rifampin Rifampin decreases the effect of clozapine (source: Drug Bank)
rifampin Rifampin decreases the effect of clozapine (source: Drug Bank)
rifampin The rifamycin decreases the effect of cyclosporine (source: Drug Bank)
rifampin The rifamycin decreases the effect of cyclosporine (source: Drug Bank)
rifampin Decreased levels of dapsone (source: Drug Bank)
rifampin Decreased levels of dapsone (source: Drug Bank)
rifampin Rifampin decreases the effect of delavirdine (source: Drug Bank)
rifampin Rifampin decreases the effect of delavirdine (source: Drug Bank)
rifampin The rifamycin decreases the effect of tricyclics (source: Drug Bank)
rifampin The rifamycin, rifampin, may decrease the effect of the tricyclic antidepressant, desipramine, by increasing its metabolism. Monitor for changes in the therapeutic and adverse effects of desipramine if rifampin is initiated, discontinued or dose changed. (source: Drug Bank)
rifampin The enzyme inducer decreases the effect of the corticosteroid (source: Drug Bank)
rifampin The enzyme inducer, rifampin, may decrease the effect of the corticosteroid, dexamethasone. (source: Drug Bank)
rifampin Rifampin decreases the effect of benzodiazepine (source: Drug Bank)
rifampin Rifampin decreases the effect of benzodiazepine (source: Drug Bank)
rifampin Decreased levels/effect of the NSAID (source: Drug Bank)
rifampin Rifampin, a CYP2C9 inducer, may increase the metabolism of diclofenac. (source: Drug Bank)
rifampin Rifampin decreases levels of diltiazem (source: Drug Bank)
rifampin Rifampin decreases levels of diltiazem (source: Drug Bank)
rifampin Rifampin decreases the effect of disopyramide (source: Drug Bank)
rifampin Rifampin decreases the effect of disopyramide (source: Drug Bank)
rifampin The rifamycin decreases the effect of tricyclics (source: Drug Bank)
rifampin The rifamycin, rifampin, may decrease the effect of the tricyclic antidepressant, doxepin, by increasing its metabolism. Monitor for changes in the therapeutic and adverse effects of doxepin if rifampin is initiated, discontinued or dose changed. (source: Drug Bank)
rifampin The rifamycin decreases the effect of doxycycline (source: Drug Bank)
rifampin The rifamycin decreases the effect of doxycycline (source: Drug Bank)
rifampin Rifampin reduces the efefct of enalapril (source: Drug Bank)
rifampin Rifampin reduces the efefct of enalapril (source: Drug Bank)
rifampin Decreased levels/effect of erlotinib (source: Drug Bank)
rifampin Decreased levels/effect of erlotinib (source: Drug Bank)
rifampin The rifamycin decreases the effect of the macrolide (source: Drug Bank)
rifampin The rifamycin, rifampin, may decrease the effect of the macrolide, erythromycin. (source: Drug Bank)
rifampin This product may cause a slight decrease of contraceptive effect (source: Drug Bank)
rifampin This product may cause a slight decrease of contraceptive effect (source: Drug Bank)
rifampin Rifampin reduces levels and efficacy of etoricoxib (source: Drug Bank)
rifampin Rifampin reduces levels and efficacy of fentanyl/alfentanyl (source: Drug Bank)
rifampin Decreases the effect of imidazole (source: Drug Bank)
rifampin Decreases the effect of imidazole (source: Drug Bank)
rifampin The enzyme inducer, rifampin, may decrease the effect of the corticosteroid, fludrocortisone. (source: Drug Bank)
rifampin The rifamycin decreases the effect of statin drug (source: Drug Bank)
rifampin The rifamycin decreases the effect of statin drug (source: Drug Bank)
rifampin In presence of rifampin anticipate decrease of amprenavir efficiency (source: Drug Bank)
rifampin In presence of rifampin anticipate decrease of amprenavir efficiency (source: Drug Bank)
rifampin Rifampin decreases the effect of hydantoin (source: Drug Bank)
rifampin Rifampin reduces levels and efficacy of gefitinib (source: Drug Bank)
rifampin Rifampin reduces levels and efficacy of gefitinib (source: Drug Bank)
rifampin Rifampin decreases the effect of sulfonylurea (source: Drug Bank)
rifampin Rifampin decreases the effect of sulfonylurea (source: Drug Bank)
rifampin Rifampin decreases the effect of sulfonylurea (source: Drug Bank)
rifampin Rifampin decreases the effect of sulfonylurea (source: Drug Bank)
rifampin Rifampin reduces levels and efficacy of rosiglitazone, rifampin decreases the effect of sulfonylurea (source: Drug Bank)
rifampin Rifampin reduces levels and efficacy of rosiglitazone, rifampin decreases the effect of sulfonylurea (source: Drug Bank)
rifampin The rifamycin decreases the effect of haloperidol (source: Drug Bank)
rifampin The rifamycin decreases the effect of haloperidol (source: Drug Bank)
rifampin The enzyme inducer decreases the effect of the corticosteroid (source: Drug Bank)
rifampin The enzyme inducer, rifampin, may decrease the effect of the corticosteroid, hydrocortisone. (source: Drug Bank)
rifampin Rifampin decreases levels of imatinib (source: Drug Bank)
rifampin Rifampin decreases levels of imatinib (source: Drug Bank)
rifampin The rifamycin decreases the effect of tricyclics (source: Drug Bank)
rifampin The rifamycin, rifampin, may decrease the effect of the tricyclic antidepressant, imipramine, by increasing its metabolism. Monitor for changes in the therapeutic and adverse effects of imipramine if rifampin is initiated, discontinued or dose changed. (source: Drug Bank)
rifampin Rifampin decreases the effect of indinavir (source: Drug Bank)
rifampin Rifampin decreases the effect of indinavir (source: Drug Bank)
rifampin Rifampin decreases the effect of the imidazole (source: Drug Bank)
rifampin Rifampin decreases the effect of the imidazole (source: Drug Bank)
rifampin Rifampin dereases the effect of the imidazole (source: Drug Bank)
rifampin Rifampin dereases the effect of the imidazole (source: Drug Bank)
rifampin Rifampin decreases levels of lamotrigine (source: Drug Bank)
rifampin Rifampin decreases levels of lamotrigine (source: Drug Bank)
rifampin Rifampin increases the effect of leflunomide (source: Drug Bank)
rifampin Rifampin increases the effect of leflunomide (source: Drug Bank)
rifampin Rifampin decreases the effect of losartan (source: Drug Bank)
rifampin Rifampin decreases the effect of losartan (source: Drug Bank)
rifampin The rifamycin decreases the effect of statin drug (source: Drug Bank)
rifampin The rifamycin decreases the effect of statin drug (source: Drug Bank)
rifampin Rifampin lowers mefloquine levels (source: Drug Bank)
rifampin Rifampin lowers mefloquine levels (source: Drug Bank)
rifampin The rifamycin decreases the effect of methadone (source: Drug Bank)
rifampin The rifamycin decreases the effect of methadone (source: Drug Bank)
rifampin Rifampin decreases the effect of the metabolized beta-blocker (source: Drug Bank)
rifampin Rifampin may decrease the serum concentration of metoprolol by increasing its metabolism. (source: Drug Bank)
rifampin Rifampin decreases the effect of mexiletine (source: Drug Bank)
rifampin Rifampin decreases the effect of mexiletine (source: Drug Bank)
rifampin Rifampin increases the effect of benzodiazepine (source: Drug Bank)
rifampin Rifampin increases the effect of benzodiazepine (source: Drug Bank)
rifampin Rifampin decreases the effect of morphine/codeine (source: Drug Bank)
rifampin Rifampin decreases the effect of morphine/codeine (source: Drug Bank)
rifampin Significant decreases in immunosuppressant levels (source: Drug Bank)
rifampin Significant decreases in immunosuppressant levels (source: Drug Bank)
rifampin Rifampin decreases the effect of nelfinavir (source: Drug Bank)
rifampin Rifampin decreases the effect of nelfinavir (source: Drug Bank)
rifampin Rifampin decreases the effect of the calcium channel blocker (source: Drug Bank)
rifampin Rifampin decreases the effect of the calcium channel blocker, nifedipine. (source: Drug Bank)
rifampin This product may cause a slight decrease of contraceptive effect (source: Drug Bank)
rifampin This product may cause a slight decrease of contraceptive effect (source: Drug Bank)
rifampin The rifamycin decreases the effect of tricyclics (source: Drug Bank)
rifampin The rifamycin, rifampin, may decrease the effect of the tricyclic antidepressant, nortriptyline, by increasing its metabolism. Monitor for changes in the therapeutic and adverse effects of nortriptyline if rifampin is initiated, discontinued or dose changed. (source: Drug Bank)
rifampin Rifampin decreases the effect and toxicity of theophylline (source: Drug Bank)
rifampin Rifampin decreases the effect of hydantoin (source: Drug Bank)
rifampin Rifampin decreases the effect of hydantoin (source: Drug Bank)
rifampin Significant decrease in praziquantel level (source: Drug Bank)
rifampin The enzyme inducer decreases the effect of the corticosteroid (source: Drug Bank)
rifampin The enzyme inducer, rifampin, may decrease the effect of the corticosteroid, prednisolone. (source: Drug Bank)
rifampin The enzyme inducer decreases the effect of the corticosteroid (source: Drug Bank)
rifampin The enzyme inducer, rifampin, may decrease the effect of the corticosteroid, prednisone. (source: Drug Bank)
rifampin Rifampin decreases the effect of propafenone (source: Drug Bank)
rifampin Rifampin decreases the effect of propafenone (source: Drug Bank)
rifampin Rifampin decreases the effect of the metabolized beta-blocker (source: Drug Bank)
rifampin Rifampin may decrease the serum concentration of propranolol by increasing its metabolism. (source: Drug Bank)
rifampin Rifampin decreases the effect of quinidine (source: Drug Bank)
rifampin Rifampin decreases the effect of quinidine (source: Drug Bank)
rifampin Rifampin reduces the levels/effect of ramelteon (source: Drug Bank)
rifampin Rifampin reduces the levels/effect of ramelteon (source: Drug Bank)
rifampin Rifampin decreases the effect of repaglinide (source: Drug Bank)
rifampin Rifampin decreases the effect of repaglinide (source: Drug Bank)
acenocoumarol The rifamycin decreases the anticoagulant effect (source: Drug Bank)
acenocoumarol Rifampin may decrease the anticoagulant effect of acenocoumarol by increasing its metabolism. (source: Drug Bank)
acetohexamide Rifampin decreases the effect of sulfonylurea (source: Drug Bank)
alfentanil Rifampin reduces levels and efficacy of alfentanil (source: Drug Bank)
alfentanil Rifampin reduces levels and efficacy of alfentanil (source: Drug Bank)
aminophylline Rifampin decreases the effect of theophylline (source: Drug Bank)
amiodarone Rifampin decreases the effect of amiodarone (source: Drug Bank)
amiodarone Rifampin decreases the effect of amiodarone (source: Drug Bank)
amitriptyline The rifamycin decreases the effect of tricyclics (source: Drug Bank)
amitriptyline The rifamycin, rifampin, may decrease the effect of the tricyclic antidepressant, amitriptyline, by increasing its metabolism. Monitor for changes in the therapeutic and adverse effects of amitriptyline if rifampin is initiated, discontinued or dose changed. (source: Drug Bank)
amoxapine The rifamycin decreases the effect of tricyclics (source: Drug Bank)
amoxapine The rifamycin, rifampin, may decrease the effect of the tricyclic antidepressant, amoxapine, by increasing its metabolism. Monitor for changes in the therapeutic and adverse effects of amoxapine if rifampin is initiated, discontinued or dose changed. (source: Drug Bank)
amprenavir In presence of rifampin, anticipate decrease of amprenavir (source: Drug Bank)
amprenavir In presence of rifampin, anticipate decrease of amprenavir (source: Drug Bank)
anisindione Rifampin may decrease the anticoagulant effect of anisindione. (source: Drug Bank)
aprepitant The CYP3A4 inducer, rifampin, may decrease the effect of aprepitant. (source: Drug Bank)
atazanavir Rifampin reduces levels and efficacy of atazanavir (source: Drug Bank)
atazanavir Rifampin reduces levels and efficacy of atazanavir (source: Drug Bank)
atorvastatin The rifamycin decreases the effect of the statin drug (source: Drug Bank)
atorvastatin The rifamycin decreases the effect of the statin drug (source: Drug Bank)
atovaquone The agent decreases the effect of atovaquone (source: Drug Bank)
atovaquone Rifampin may decrease the effect of atovaquone. (source: Drug Bank)
betamethasone The enzyme inducer, rifampin, may decrease the effect of the corticosteroid, betamethasone. (source: Drug Bank)
bisoprolol Rifampin decreases the effect of the metabolized beta-blocker (source: Drug Bank)
bisoprolol Rifampin may decrease the serum concentration of bisprolol by increasing its metabolism. (source: Drug Bank)
bupropion Rifampin reduces bupropion levels (source: Drug Bank)
bupropion Rifampin reduces bupropion levels (source: Drug Bank)
buspirone Rifampin decreases the effect of buspirone (source: Drug Bank)
caspofungin Decreased levels/effects of caspofungin (source: Drug Bank)
celecoxib Decreased levels/effect of the NSAID (source: Drug Bank)
celecoxib Rifampin, a strong CYP2C9 inducer, may decrease the serum levels of celecoxib by increasing its metabolism. Monitor for changes in the therapeutic and adverse effects if rifampin is initiated, discontinued or dose changed. (source: Drug Bank)
cerivastatin The rifamycin decreases the effect of the statin drug (source: Drug Bank)
cerivastatin The rifamycin decreases the effect of the statin drug (source: Drug Bank)
chloramphenicol Rifampin decreases the effect of chloramphenicol (source: Drug Bank)
chloramphenicol Rifampin decreases the effect of chloramphenicol (source: Drug Bank)
chlorpropamide Rifampin decreases the effect of sulfonylurea (source: Drug Bank)
chlorpropamide Rifampin decreases the effect of sulfonylurea (source: Drug Bank)
clarithromycin The rifamycin decreases the effect of the macrolide (source: Drug Bank)
clarithromycin The rifamycin, rifampin, may decrease the effect of the macrolide, clarithromycin. (source: Drug Bank)
clomipramine The rifamycin decreases the effect of tricyclics (source: Drug Bank)
clomipramine The rifamycin, rifampin, may decrease the effect of the tricyclic antidepressant, clomipramine, by increasing its metabolism. Monitor for changes in the therapeutic and adverse effects of clomipramine if rifampin is initiated, discontinued or dose changed. (source: Drug Bank)
clozapine Rifampin decreases the effect of clozapine (source: Drug Bank)
clozapine Rifampin decreases the effect of clozapine (source: Drug Bank)
cortisone acetate The enzyme inducer decreases the effect of the corticosteroid (source: Drug Bank)
cyclosporine The rifamycin decreases the effect of cyclosporine (source: Drug Bank)
cyclosporine The rifamycin decreases the effect of cyclosporine (source: Drug Bank)
dapsone Decreased levels of dapsone (source: Drug Bank)
dapsone Decreased levels of dapsone (source: Drug Bank)
dasatinib Decreased levels/efficacy of dasatinib (source: Drug Bank)
dasatinib Rifampin may decrease the serum level and efficacy of dasatinib. (source: Drug Bank)
delavirdine Rifampin decreases the effect of delavirdine (source: Drug Bank)
delavirdine Rifampin decreases the effect of delavirdine (source: Drug Bank)
desipramine The rifamycin decreases the effect of tricyclics (source: Drug Bank)
desipramine The rifamycin, rifampin, may decrease the effect of the tricyclic antidepressant, desipramine, by increasing its metabolism. Monitor for changes in the therapeutic and adverse effects of desipramine if rifampin is initiated, discontinued or dose changed. (source: Drug Bank)
dexamethasone The enzyme inducer decreases the effect of the corticosteroid (source: Drug Bank)
dexamethasone The enzyme inducer, rifampin, may decrease the effect of the corticosteroid, dexamethasone. (source: Drug Bank)
diazepam Rifampin decreases the effect of benzodiazepine (source: Drug Bank)
diazepam Rifampin decreases the effect of benzodiazepine (source: Drug Bank)
diclofenac Decreased levels/effect of the NSAID (source: Drug Bank)
dicumarol The rifamycin decreases the anticoagulant effect (source: Drug Bank)
dicumarol Rifampin may decrease the anticoagulant effect of dicumarol. (source: Drug Bank)
diltiazem Rifampin decreases levels of diltiazem (source: Drug Bank)
diltiazem Rifampin decreases levels of diltiazem (source: Drug Bank)
disopyramide Rifampin decreases the effect of disopyramide (source: Drug Bank)
disopyramide Rifampin decreases the effect of disopyramide (source: Drug Bank)
doxepin The rifamycin decreases the effect of tricyclics (source: Drug Bank)
doxepin The rifamycin, rifampin, may decrease the effect of the tricyclic antidepressant, doxepin, by increasing its metabolism. Monitor for changes in the therapeutic and adverse effects of doxepin if rifampin is initiated, discontinued or dose changed. (source: Drug Bank)
doxycycline The rifamycin decreases the effect of doxycycline (source: Drug Bank)
doxycycline The rifamycin decreases the effect of doxycycline (source: Drug Bank)
dyphylline Rifampin decreases the effect of theophylline (source: Drug Bank)
enalapril Rifampin decreases the effect of enalapril (source: Drug Bank)
enalapril Rifampin decreases the effect of enalapril (source: Drug Bank)
erlotinib Decreased levels/effect of erlotinib (source: Drug Bank)
erlotinib Decreased levels/effect of erlotinib (source: Drug Bank)
erythromycin The rifamycin decreases the effect of the macrolide (source: Drug Bank)
erythromycin The rifamycin, rifampin, may decrease the effect of the macrolide, erythromycin. (source: Drug Bank)
ethinyl estradiol This product may cause a slight decrease of contraceptive effect (source: Drug Bank)
ethotoin Rifampin decreases the effect of the hydantoin (source: Drug Bank)
etoricoxib Rifampin reduces levels and efficacy of etoricoxib (source: Drug Bank)
fentanyl Rifampin reduces levels and efficacy of alfentanil (source: Drug Bank)
fentanyl Rifampin reduces levels and efficacy of alfentanil (source: Drug Bank)
fluconazole Fluconazole decreases the effect of imidazole (source: Drug Bank)
fluconazole Fluconazole decreases the effect of imidazole (source: Drug Bank)
fludrocortisone The enzyme inducer, rifampin, may decrease the effect of the corticosteroid, fludrocortisone. (source: Drug Bank)
fluvastatin The rifamycin decreases the effect of the statin drug (source: Drug Bank)
fluvastatin The rifamycin decreases the effect of the statin drug (source: Drug Bank)
fosamprenavir In presence of rifampin, anticipate decrease of amprenavir (source: Drug Bank)
fosamprenavir In presence of rifampin, anticipate decrease of amprenavir (source: Drug Bank)
fosphenytoin Rifampin decreases the effect of the hydantoin (source: Drug Bank)
gefitinib Rifampin reduces levels and efficacy of gefitinib (source: Drug Bank)
gefitinib Rifampin reduces levels and efficacy of gefitinib (source: Drug Bank)
glibenclamide Rifampin decreases the effect of sulfonylurea (source: Drug Bank)
glibenclamide Rifampin decreases the effect of sulfonylurea (source: Drug Bank)
gliclazide Rifampin decreases the effect of sulfonylurea (source: Drug Bank)
gliclazide Rifampin decreases the effect of sulfonylurea (source: Drug Bank)
glimepiride Rifampin decreases the effect of sulfonylurea (source: Drug Bank)
glimepiride Rifampin decreases the effect of sulfonylurea (source: Drug Bank)
glipizide Rifampin decreases the effect of sulfonylurea (source: Drug Bank)
glipizide Rifampin decreases the effect of sulfonylurea (source: Drug Bank)
glisoxepide Rifampin decreases the effect of sulfonylurea (source: Drug Bank)
glycodiazine Rifampin decreases the effect of sulfonylurea (source: Drug Bank)
haloperidol The rifamycin decreases the effect of haloperidol (source: Drug Bank)
haloperidol The rifamycin decreases the effect of haloperidol (source: Drug Bank)
hydrocortisone The enzyme inducer decreases the effect of the corticosteroid (source: Drug Bank)
hydrocortisone The enzyme inducer, rifampin, may decrease the effect of the corticosteroid, hydrocortisone. (source: Drug Bank)
imatinib Rifampin decreases levels of imatinib (source: Drug Bank)
imatinib Rifampin decreases levels of imatinib (source: Drug Bank)
imipramine The rifamycin decreases the effect of tricyclics (source: Drug Bank)
imipramine The rifamycin, rifampin, may decrease the effect of the tricyclic antidepressant, imipramine, by increasing its metabolism. Monitor for changes in the therapeutic and adverse effects of imipramine if rifampin is initiated, discontinued or dose changed. (source: Drug Bank)
indinavir Rifampin decreases the effect of indinavir (source: Drug Bank)
indinavir Rifampin decreases the effect of indinavir (source: Drug Bank)
itraconazole Rifampin decreases the effect of the imidazole (source: Drug Bank)
itraconazole Rifampin decreases the effect of the imidazole (source: Drug Bank)
josamycin The rifamycin, rifampin, may decrease the effect of the macrolide, josamycin. (source: Drug Bank)
ketoconazole Rifampin decreases the effect of the imidazole (source: Drug Bank)
ketoconazole Rifampin decreases the effect of the imidazole (source: Drug Bank)
lamotrigine Rifampin decreases levels of lamotrigine (source: Drug Bank)
lamotrigine Rifampin decreases levels of lamotrigine (source: Drug Bank)
leflunomide Rifampin increases the effect of leflunomide (source: Drug Bank)
leflunomide Rifampin increases the effect of leflunomide (source: Drug Bank)
losartan Rifampin decreases the effect of losartan (source: Drug Bank)
losartan Rifampin decreases the effect of losartan (source: Drug Bank)
lovastatin The rifamycin decreases the effect of the statin drug (source: Drug Bank)
lovastatin The rifamycin decreases the effect of the statin drug (source: Drug Bank)
mefloquine Rifampin lowers mefloquine levels (source: Drug Bank)
mefloquine Rifampin lowers mefloquine levels (source: Drug Bank)
mephenytoin Rifampin decreases the effect of the hydantoin (source: Drug Bank)
mephenytoin Rifampin decreases the effect of the hydantoin (source: Drug Bank)
mestranol This product may cause a slight decrease of contraceptive effect (source: Drug Bank)
mestranol This product may cause a slight decrease of contraceptive effect (source: Drug Bank)
methadone The rifamycin decreases the effect of methadone (source: Drug Bank)
methadone The rifamycin decreases the effect of methadone (source: Drug Bank)
methylprednisolone The enzyme inducer decreases the effect of the corticosteroid (source: Drug Bank)
methylprednisolone The enzyme inducer, rifampin, may decrease the effect of the corticosteroid, methylprednisolone. (source: Drug Bank)
metoprolol Rifampin decreases the effect of the metabolized beta-blocker (source: Drug Bank)
metoprolol Rifampin may decrease the serum concentration of metoprolol by increasing its metabolism. (source: Drug Bank)
mexiletine Rifampin decreases the effect of mexiletine (source: Drug Bank)
mexiletine Rifampin decreases the effect of mexiletine (source: Drug Bank)
midazolam Rifampin decreases the effect of benzodiazepine (source: Drug Bank)
midazolam Rifampin decreases the effect of benzodiazepine (source: Drug Bank)
morphine Rifampin decreases the effect of morphine/codeine (source: Drug Bank)
morphine Rifampin decreases the effect of morphine/codeine (source: Drug Bank)
mycophenolate mofetil Significant decrease in immunosuppressant levels (source: Drug Bank)
nelfinavir Rifampin decreases the effect of nelfinavir (source: Drug Bank)
nelfinavir Rifampin decreases the effect of nelfinavir (source: Drug Bank)
nifedipine Rifampin decreases the effect of the calcium channel blocker (source: Drug Bank)
nifedipine Rifampin decreases the effect of the calcium channel blocker, nifedipine. (source: Drug Bank)
norethindrone This product may cause a slight decrease of contraceptive effect (source: Drug Bank)
norethindrone This product may cause a slight decrease of contraceptive effect (source: Drug Bank)
nortriptyline The rifamycin decreases the effect of tricyclics (source: Drug Bank)
nortriptyline The rifamycin, rifampin, may decrease the effect of the tricyclic antidepressant, nortriptyline, by increasing its metabolism. Monitor for changes in the therapeutic and adverse effects of nortriptyline if rifampin is initiated, discontinued or dose changed. (source: Drug Bank)
oxtriphylline Rifampin decreases the effect of theophylline (source: Drug Bank)
paramethasone The enzyme inducer, rifampin, may decrease the effect of the corticosteroid, paramethasone. (source: Drug Bank)
phenytoin Rifampin decreases the effect of the hydantoin (source: Drug Bank)
phenytoin Rifampin decreases the effect of the hydantoin (source: Drug Bank)
praziquantel Significant decrease in praziquantel level (source: Drug Bank)
prednisolone The enzyme inducer decreases the effect of the corticosteroid (source: Drug Bank)
prednisolone The enzyme inducer, rifampin, may decrease the effect of the corticosteroid, prednisolone. (source: Drug Bank)
prednisone The enzyme inducer decreases the effect of the corticosteroid (source: Drug Bank)
prednisone The enzyme inducer, rifampin, may decrease the effect of the corticosteroid, prednisone. (source: Drug Bank)
propafenone Rifampin decreases the effect of propafenone (source: Drug Bank)
propafenone Rifampin decreases the effect of propafenone (source: Drug Bank)
propranolol Rifampin decreases the effect of the metabolized beta-blocker (source: Drug Bank)
propranolol Rifampin may decrease the serum concentration of propranolol by increasing its metabolism. (source: Drug Bank)
protriptyline The rifamycin decreases the effect of tricyclics (source: Drug Bank)
protriptyline The rifamycin, rifampin, may decrease the effect of the tricyclic antidepressant, protriptyline, by increasing its metabolism. Monitor for changes in the therapeutic and adverse effects of protriptyline if rifampin is initiated, discontinued or dose changed. (source: Drug Bank)
quinidine Rifampin decreases the effect of quinidine (source: Drug Bank)
quinidine Rifampin decreases the effect of quinidine (source: Drug Bank)
ramelteon Rifampin reduces the levels/effect of ramelteon (source: Drug Bank)
repaglinide Rifampin decreases the effect of repaglinide (source: Drug Bank)
repaglinide Rifampin decreases the effect of repaglinide (source: Drug Bank)
ritonavir Rifampin decreases the effect of ritonavir (source: Drug Bank)
ritonavir Rifampin decreases the effect of ritonavir (source: Drug Bank)
rofecoxib Decreased levels/effect of the NSAID (source: Drug Bank)
rosiglitazone Rifampin reduces levels and efficacy of rosiglitazone (source: Drug Bank)
rosiglitazone Rifampin reduces levels and efficacy of rosiglitazone (source: Drug Bank)
saquinavir Rifampin decreases the effect of saquinavir (source: Drug Bank)
saquinavir Rifampin decreases the effect of saquinavir (source: Drug Bank)
simvastatin The rifamycin decreases the effect of the statin drug (source: Drug Bank)
simvastatin The rifamycin decreases the effect of the statin drug (source: Drug Bank)
sirolimus The rifamycin decreases the effect of sirolimus (source: Drug Bank)
sirolimus The rifamycin decreases the effect of sirolimus (source: Drug Bank)
sunitinib Possible decrease in sunitinib levels (source: Drug Bank)
sunitinib Possible decrease in sunitinib levels (source: Drug Bank)
tacrolimus The rifamycin decreases the effect of tacrolimus (source: Drug Bank)
tacrolimus The rifamycin decreases the effect of tacrolimus (source: Drug Bank)
tadalafil Rifampin reduces levels and efficacy of tadalafil (source: Drug Bank)
tadalafil Rifampin reduces levels and efficacy of tadalafil (source: Drug Bank)
tamoxifen The rifamycin decreases the effect of anti-estrogen (source: Drug Bank)
tamoxifen The rifamycin decreases the effect of anti-estrogen (source: Drug Bank)
telithromycin Rifampin decreases the effect of telithromycin (source: Drug Bank)
telithromycin Rifampin decreases the effect of telithromycin (source: Drug Bank)
terbinafine Rifampin decreases the effect of terbinafine (source: Drug Bank)
terbinafine Rifampin decreases the effect of terbinafine (source: Drug Bank)
theophylline Rifampin decreases the effect of theophylline (source: Drug Bank)
theophylline Rifampin decreases the effect of theophylline (source: Drug Bank)
tocainide Rifampin lowers tocainide levels/effects (source: Drug Bank)
tocainide Rifampin lowers tocainide levels/effects (source: Drug Bank)
tolazamide Rifampin decreases the effect of sulfonylurea (source: Drug Bank)
tolbutamide Rifampin decreases the effect of sulfonylurea (source: Drug Bank)
tolbutamide Rifampin decreases the effect of sulfonylurea (source: Drug Bank)
toremifene The rifamycin decreases the effect of anti-estrogen (source: Drug Bank)
toremifene The rifamycin decreases the effect of anti-estrogen (source: Drug Bank)
triamcinolone The enzyme inducer decreases the effect of the corticosteroid (source: Drug Bank)
triamcinolone The enzyme inducer, rifampin, may decrease the effect of the corticosteroid, triamcinolone. (source: Drug Bank)
triazolam Rifampin decreases the effect of benzodiazepine (source: Drug Bank)
triazolam Rifampin decreases the effect of benzodiazepine (source: Drug Bank)
trimethoprim Rifampin decreases the effect of trimethoprim (source: Drug Bank)
trimethoprim Rifampin decreases the effect of trimethoprim (source: Drug Bank)
trimipramine The rifamycin decreases the effect of tricyclics (source: Drug Bank)
trimipramine The rifamycin, rifampin, may decrease the effect of the tricyclic antidepressant, trimipramine, by increasing its metabolism. Monitor for changes in the therapeutic and adverse effects of trimipramine if rifampin is initiated, discontinued or dose changed. (source: Drug Bank)
verapamil Rifampin decreases the effect of the calcium channel blocker (source: Drug Bank)
verapamil Rifampin decreases the effect of the calcium channel blocker, verapamil. (source: Drug Bank)
voriconazole Rifampin decreases the effect of voriconazole (source: Drug Bank)
voriconazole Rifampin decreases the effect of voriconazole (source: Drug Bank)
warfarin The rifamycin decreases the anticoagulant effect (source: Drug Bank)
warfarin Rifampin may decrease the anticoagulant effect of warfarin by increasing its metabolism. (source: Drug Bank)
zaleplon Rifampin decreases the effect of zaleplon (source: Drug Bank)
zaleplon Rifampin decreases the effect of zaleplon (source: Drug Bank)
zidovudine The rifamycin decreases levels of zidovudine (source: Drug Bank)
zidovudine The rifamycin decreases levels of zidovudine (source: Drug Bank)
rifampin Rifampin may decrease the blood concentration of Tacrolimus. Monitor for changes in the therapeutic/toxic effects of Tacrolimus if Rifampin therapy is initiated, discontinued or altered. (source: Drug Bank)
rifampin Rifampin may reduce Tadalafil plasma concentrations and efficacy. (source: Drug Bank)
rifampin Rifampin decreases the effect of telithromycin (source: Drug Bank)
rifampin Rifampin may decrease the plasma concentration of Telithromycin. Concomitant therapy should be avoided. (source: Drug Bank)
rifampin Rifampin may increase the metabolism of Temsirolimus decreasing its efficacy. Concomitant therapy should be avoided. (source: Drug Bank)
rifampin Rifampin decreases the effect of terbinafine (source: Drug Bank)
rifampin Rifampin may increase the metabolism and clearance of Terbinafine. Co-administration may result in Terbinafine treatment failure. (source: Drug Bank)
rifampin Rifampin decreases the effect of theophylline (source: Drug Bank)
rifampin Rifampin decreases the effect of theophylline (source: Drug Bank)
rifampin Rifampin may decrease the plasma concentration of Tipranavir. Concomitant use is not recommended. (source: Drug Bank)
rifampin Rifampin may decrease the effect of Tramadol by increasing Tramadol metabolism and clearance. (source: Drug Bank)
rifampin The CYP3A4 inducer, Rifampin, may decrease Trazodone efficacy by increasing Trazodone metabolism and clearance. Monitor for changes in Trazodone efficacy/toxicity if Rifampin is initiated, discontinued or dose changed. (source: Drug Bank)
rifampin The CYP3A4 inducer, Rifampin, may decrease Trazodone efficacy by increasing Trazodone metabolism and clearance. Monitor for changes in Trazodone efficacy/toxicity if Rifampin is initiated, discontinued or dose changed. (source: Drug Bank)
rifampin The strong CYP2C8 inducer, Rifampin, may increase the metabolism and clearance of oral Tretinoin. Consider alternate therapy to avoid failure of Tretinoin therapy or monitor for changes in Tretinoin effectiveness and adverse/toxic effects if Rifampin is initiated, discontinued or dose changed. (source: Drug Bank)
rifampin The enzyme inducer decreases the effect of the corticosteroid (source: Drug Bank)
rifampin The enzyme inducer, rifampin, may decrease the effect of the corticosteroid, triamcinolone. (source: Drug Bank)
rifampin Rifampin decreases the effect of the benzodiazepine (source: Drug Bank)
rifampin Rifampin decreases the effect of the benzodiazepine (source: Drug Bank)
rifampin Rifampin may reduce the serum concentration of Valproic acid by increasing Valproic acid metabolism. Valproic acid dose adjustments may be required during concomitant therapy. Monitor Valproic acid serum concentrations, efficacy and toxicity if Rifampin is initiated, discontinued or dose changed. (source: Drug Bank)
rifampin Rifampin, a CYP3A4 inducer, may decrease the serum concentration of Verapamil by increasing its metabolism (particularly in the intestinal mucosa) and decreasing its absorption. Monitor for changes in the therapeutic/adverse effects of Verapamil if Rifampin is initiated, discontinued or dose changed. (source: Drug Bank)
rifampin Rifampin may decrease the serum concentration of voriconazole likely by increasing its metabolism via CYP3A enzymes. Voriconazole may increase the serum concentration of rifampin likely by inhibiting its metabolism via CYP3A. Concomitant therapy is contraindicated. (source: Drug Bank)
rifampin Rifampin may decrease the serum concentration of zidovudine by increasing its metabolism. Monitor for changes in the serum concentration and therapeutic and adverse effects of zidovudine if rifampin is initiated, discontinued or dose changed. (source: Drug Bank)

Curated Information ?

Relationships from National Drug File - Reference Terminology (NDF-RT)

May Treat
May Prevent
Contraindicated With

Publications related to rifampin: 163

No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available No VIP available No VIP available
Comparison of two endogenous biomarkers of CYP3A4 activity in a drug-drug interaction study between midostaurin and rifampicin. European journal of clinical pharmacology. 2014. Dutreix Catherine, et al. PubMed
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available No VIP available No VIP available
Human UGT1A4 and UGT1A3 Conjugate 25-Hydroxyvitamin D3: Metabolite Structure, Kinetics, Inducibility and Interindividual Variability. Endocrinology. 2014. Wang Zhican, et al. PubMed
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available No VIP available No VIP available
Evolution and transmission of drug-resistant tuberculosis in a Russian population. Nature genetics. 2014. Casali Nicola, et al. PubMed
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available No VIP available No VIP available
In vitro OATP1B1 and OATP1B3 inhibition is associated with observations of benign clinical unconjugated hyperbilirubinemia. Xenobiotica; the fate of foreign compounds in biological systems. 2014. Chiou William J, et al. PubMed
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available No VIP available No VIP available
Understanding variability with voriconazole using a population pharmacokinetic approach: implications for optimal dosing. The Journal of antimicrobial chemotherapy. 2014. Dolton Michael J, et al. PubMed
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available No VIP available No VIP available
Dependence of efavirenz- and rifampicin-isoniazid-based antituberculosis treatment drug-drug interaction on CYP2B6 and NAT2 genetic polymorphisms: ANRS 12154 study in Cambodia. The Journal of infectious diseases. 2014. Bertrand Julie, et al. PubMed
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available No VIP available No VIP available
Impact of CYP polymorphisms, ethnicity and sex differences in metabolism on dosing strategies: the case of efavirenz. European journal of clinical pharmacology. 2014. Naidoo Panjasaram, et al. PubMed
No Dosing Guideline available No Drug Label available No Clinical Annotation available VA No VIP available No VIP available
Factors Associated with Variability in Rifampin Plasma Pharmacokinetics and the Relationship between Rifampin Concentrations and Induction of Efavirenz Clearance. Pharmacotherapy. 2014. Kwara Awewura, et al. PubMed
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available No VIP available No VIP available
Genomic analysis identifies targets of convergent positive selection in drug-resistant Mycobacterium tuberculosis. Nature genetics. 2013. Farhat Maha R, et al. PubMed
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available No VIP available No VIP available
Regulation of miRNA Expression by Rifampin in Human Hepatocytes. Drug metabolism and disposition: the biological fate of chemicals. 2013. Ramamoorthy Anuradha, et al. PubMed
No Dosing Guideline available No Drug Label available No Clinical Annotation available VA No VIP available No VIP available
Association of N-acetyltransferase 2 and cytochrome P450 2E1 gene polymorphisms with antituberculosis drug-induced hepatotoxicity in Western India. Journal of gastroenterology and hepatology. 2013. Gupta Vinod H, et al. PubMed
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available No VIP available No VIP available
Mycobacterium tuberculosis mutation rate estimates from different lineages predict substantial differences in the emergence of drug-resistant tuberculosis. Nature genetics. 2013. Ford Christopher B, et al. PubMed
No Dosing Guideline available No Drug Label available No Clinical Annotation available VA No VIP available No VIP available
N-acetyl transferase 2 and cytochrome P450 2E1 genes and isoniazid-induced hepatotoxicity in Brazilian patients. The international journal of tuberculosis and lung disease : the official journal of the International Union against Tuberculosis and Lung Disease. 2013. Santos N P C, et al. PubMed
No Dosing Guideline available No Drug Label available No Clinical Annotation available VA No VIP available No VIP available
Relationship of NAT2, CYP2E1 and GSTM1/GSTT1 polymorphisms with mild elevation of liver enzymes in Brazilian individuals under anti-tuberculosis drug therapy. Clinica chimica acta; international journal of clinical chemistry. 2013. Forestiero Francisco Jose, et al. PubMed
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available No VIP available No VIP available
Enhancement of hepatic 4-hydroxylation of 25-hydroxyvitamin D(3) through CYP3A4 induction in vitro and in vivo: Implications for drug-induced osteomalacia. Journal of bone and mineral research : the official journal of the American Society for Bone and Mineral Research. 2012. Wang Zhican, et al. PubMed
No Dosing Guideline available No Drug Label available CA No Variant Annotation available No VIP available No VIP available
The roles of GSTM1 and GSTT1 null genotypes and other predictors in anti-tuberculosis drug-induced liver injury. Journal of clinical pharmacy and therapeutics. 2012. Monteiro T P, et al. PubMed
No Dosing Guideline available No Drug Label available No Clinical Annotation available VA No VIP available No VIP available
Sex, ethnicity and slow acetylator profile are the major causes of hepatotoxicity induced by antituberculosis drugs. Journal of gastroenterology and hepatology. 2012. Chamorro Julián G, et al. PubMed
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available No VIP available No VIP available
Sulforaphane is not an effective antagonist of the human pregnane X-receptor in vivo. Toxicology and applied pharmacology. 2012. Poulton Emma Jane, et al. PubMed
No Dosing Guideline available No Drug Label available CA VA No VIP available No VIP available
CYP2E1, GSTM1 and GSTT1 genetic polymorphisms and susceptibility to antituberculosis drug-induced hepatotoxicity: a nested case-control study. Journal of clinical pharmacy and therapeutics. 2012. Tang S-W, et al. PubMed
No Dosing Guideline available No Drug Label available No Clinical Annotation available VA No VIP available No VIP available
Polymorphism of the N-acetyltransferase 2 gene as a susceptibility risk factor for antituberculosis drug-induced hepatotoxicity in Tunisian patients with tuberculosis. Pathologie-biologie. 2012. Ben Mahmoud L, et al. PubMed
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available No VIP available No VIP available
Human PXR-mediated induction of intestinal CYP3A4 attenuates 1alpha,25-dihydroxyvitamin D₃ function in human colon adenocarcinoma LS180 cells. Biochemical pharmacology. 2012. Zheng Xi Emily, et al. PubMed
No Dosing Guideline available No Drug Label available CA VA No VIP available No VIP available
Genetic interaction between NAT2, GSTM1, GSTT1, CYP2E1, and environmental factors is associated with adverse reactions to anti-tuberculosis drugs. Molecular diagnosis & therapy. 2012. Costa Gustavo N O, et al. PubMed
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available No VIP available No VIP available
The Dual Role of Pharmacogenetics in HIV Treatment: Mutations and Polymorphisms Regulating Antiretroviral Drug Resistance and Disposition. Pharmacological reviews. 2012. Michaud Veronique, et al. PubMed
No Dosing Guideline available No Drug Label available No Clinical Annotation available VA No VIP available No VIP available
NAT2 and CYP2E1 polymorphisms associated with antituberculosis drug-induced hepatotoxicity in Chinese patients. Clinical and experimental pharmacology & physiology. 2012. An Hui-Ru, et al. PubMed
No Dosing Guideline available No Drug Label available No Clinical Annotation available VA No VIP available No VIP available
TNF-alpha genetic polymorphism -308G/A and antituberculosis drug-induced hepatitis. Liver international : official journal of the International Association for the Study of the Liver. 2012. Kim Sang-Heon, et al. PubMed
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available No VIP available No VIP available
NAT2 polymorphisms and susceptibility to anti-tuberculosis drug-induced liver injury: a meta-analysis. The international journal of tuberculosis and lung disease : the official journal of the International Union against Tuberculosis and Lung Disease. 2012. Wang P-Y, et al. PubMed
No Dosing Guideline available No Drug Label available CA VA No VIP available No VIP available
Genetic variants in antioxidant pathway: risk factors for hepatotoxicity in tuberculosis patients. Tuberculosis (Edinburgh, Scotland). 2012. Nanashima Kazutaka, et al. PubMed
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available No VIP available No VIP available
Complex drug interactions of the HIV protease inhibitors 3: effect of simultaneous or staggered dosing of digoxin and ritonavir, nelfinavir, rifampin, or bupropion. Drug metabolism and disposition: the biological fate of chemicals. 2012. Kirby Brian J, et al. PubMed
No Dosing Guideline available No Drug Label available No Clinical Annotation available VA No VIP available No VIP available
NAT2 genetic polymorphisms and anti-tuberculosis drug-induced hepatotoxicity in Chinese community population. Annals of hepatology. 2012. Lv Xiaozhen, et al. PubMed
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available No VIP available No VIP available
Pharmacogenetic study of drug-metabolising enzyme polymorphisms on the risk of anti-tuberculosis drug-induced liver injury: a meta-analysis. PloS one. 2012. Cai Yu, et al. PubMed
No Dosing Guideline available No Drug Label available No Clinical Annotation available VA No VIP available No VIP available
Relationship between CYP2E1 polymorphism and increase of ALT activity during therapy of patients with pulmonary tuberculosis. Bulletin of experimental biology and medicine. 2011. Kudryashov A V, et al. PubMed
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available No VIP available No VIP available
Clinical pharmacology profile of raltegravir, an HIV-1 integrase strand transfer inhibitor. Journal of clinical pharmacology. 2011. Brainard Diana M, et al. PubMed
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available VIP No VIP available
PharmGKB summary: very important pharmacogene information for cytochrome P450, family 2, subfamily C, polypeptide 19. Pharmacogenetics and genomics. 2011. Scott Stuart A, et al. PubMed
No Dosing Guideline available No Drug Label available No Clinical Annotation available VA No VIP available No VIP available
N-acetyltransferase 2 polymorphisms and risk of anti-tuberculosis drug-induced hepatotoxicity in Caucasians. The international journal of tuberculosis and lung disease : the official journal of the International Union against Tuberculosis and Lung Disease. 2011. Leiro-Fernandez V, et al. PubMed
No Dosing Guideline available No Drug Label available No Clinical Annotation available VA No VIP available No VIP available
The SLCO1B1 rs4149032 polymorphism is highly prevalent in South Africans and is associated with reduced rifampin concentrations: dosing implications. Antimicrobial agents and chemotherapy. 2011. Chigutsa Emmanuel, et al. PubMed
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available No VIP available No VIP available
Complex Drug Interactions of HIV Protease Inhibitors 2: In Vivo Induction and In Vitro to In Vivo Correlation of Induction of Cytochrome P450 1A2, 2B6 and 2C9 by Ritonavir or Nelfinavir. Drug metabolism and disposition: the biological fate of chemicals. 2011. Kirby Brian J, et al. PubMed
No Dosing Guideline available No Drug Label available CA No Variant Annotation available No VIP available No VIP available
SLCO1B1 haplotypes are not associated with atorvastatin-induced myalgia in Brazilian patients with familial hypercholesterolemia. European journal of clinical pharmacology. 2011. Santos Paulo Caleb Junior Lima, et al. PubMed
No Dosing Guideline available No Drug Label available CA No Variant Annotation available No VIP available No VIP available
Genetic polymorphisms of NAT2, CYP2E1 and GST enzymes and the occurrence of antituberculosis drug-induced hepatitis in Brazilian TB patients. Memórias do Instituto Oswaldo Cruz. 2011. Teixeira Raquel Lima de Figueiredo, et al. PubMed
No Dosing Guideline available No Drug Label available No Clinical Annotation available VA No VIP available No VIP available
Effect of Rifampicin and CYP2B6 Genotype on Long-Term Efavirenz Autoinduction and Plasma Exposure in HIV Patients With or Without Tuberculosis. Clinical pharmacology and therapeutics. 2011. Ngaimisi E, et al. PubMed
No Dosing Guideline available No Drug Label available No Clinical Annotation available VA No VIP available No VIP available
Comparison between acetylator phenotype and genotype polymorphism of n-acetyltransferase-2 in tuberculosis patients. Hepatology international. 2011. Rana S V, et al. PubMed
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available No VIP available No VIP available
Contribution of N-glucuronidation to efavirenz elimination in vivo in the basal and rifampin-induced metabolism of efavirenz. Antimicrobial agents and chemotherapy. 2011. Cho Doo-Yeoun, et al. PubMed
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available No VIP available No VIP available
Rifampin enhances the glucose-lowering effect of metformin and increases OCT1 mRNA levels in healthy participants. Clinical pharmacology and therapeutics. 2011. Cho S K, et al. PubMed
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available No VIP available No VIP available
Complex Drug Interactions of HIV Protease Inhibitors 1: Inactivation, Induction and Inhibition of Cytochrome P450 3A by Ritonavir or Nelfinavir. Drug metabolism and disposition: the biological fate of chemicals. 2011. Kirby Brian J, et al. PubMed
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available VIP No VIP available
Very important pharmacogene summary: ABCB1 (MDR1, P-glycoprotein). Pharmacogenetics and genomics. 2011. Hodges Laura M, et al. PubMed
No Dosing Guideline available No Drug Label available No Clinical Annotation available VA No VIP available No VIP available
Association of N-acetyltransferase-2 genotypes and anti-tuberculosis induced liver injury; first case-controlled study from Iran. Current drug safety. 2011. Khalili Hossein, et al. PubMed
No Dosing Guideline available No Drug Label available No Clinical Annotation available VA No VIP available No VIP available
NAT2, CYP2C9, CYP2C19, and CYP2E1 genetic polymorphisms in anti-TB drug-induced maculopapular eruption. European journal of clinical pharmacology. 2011. Kim Sang-Heon, et al. PubMed
No Dosing Guideline available No Drug Label available No Clinical Annotation available VA No VIP available No VIP available
Role of polymorphic N-acetyl transferase2 and cytochrome P4502E1 gene in antituberculosis treatment-induced hepatitis. Journal of gastroenterology and hepatology. 2011. Bose Purabi Deka, et al. PubMed
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available No VIP available No VIP available
Effects of pregnane X receptor (NR1I2) and CYP2B6 genetic polymorphisms on the induction of bupropion hydroxylation by rifampin. Drug metabolism and disposition: the biological fate of chemicals. 2011. Chung Jae Yong, et al. PubMed
No Dosing Guideline available No Drug Label available CA No Variant Annotation available No VIP available No VIP available
Differential effect of the rs4149056 variant in SLCO1B1 on myopathy associated with simvastatin and atorvastatin. The pharmacogenomics journal. 2011. Brunham L R, et al. PubMed
No Dosing Guideline available No Drug Label available CA VA No VIP available No VIP available
Association of isoniazid-metabolizing enzyme genotypes and isoniazid-induced hepatotoxicity in tuberculosis patients. In vivo (Athens, Greece). 2011. Sotsuka Takayo, et al. PubMed
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available No VIP available No VIP available
Nuclear receptor-mediated induction of CYP450 by antiretrovirals: functional consequences of NR1I2 (PXR) polymorphisms and differential prevalence in whites and sub-Saharan Africans. Journal of acquired immune deficiency syndromes (1999). 2010. Svärd Jenny, et al. PubMed
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available No VIP available No VIP available
Systematic review of pharmacoeconomic studies of pharmacogenomic tests. Pharmacogenomics. 2010. Beaulieu Mathieu, et al. PubMed
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available No VIP available No VIP available
Effect of single-dose rifampin on the pharmacokinetics of warfarin in healthy volunteers. Clinical pharmacology and therapeutics. 2010. Frymoyer A, et al. PubMed
No Dosing Guideline available No Drug Label available CA VA No VIP available No VIP available
GSTT1 and GSTM1 gene deletions are not associated with hepatotoxicity caused by antitubercular drugs. Journal of clinical pharmacy and therapeutics. 2010. Chatterjee S, et al. PubMed
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available VIP No VIP available
PharmGKB summary: very important pharmacogene information for CYP2B6. Pharmacogenetics and genomics. 2010. Thorn Caroline F, et al. PubMed
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available No VIP available No VIP available
Pharmacokinetic and pharmacodynamic interactions between the immunosuppressant sirolimus and the lipid-lowering drug ezetimibe in healthy volunteers. Clinical pharmacology and therapeutics. 2010. Oswald S, et al. PubMed
No Dosing Guideline available No Drug Label available No Clinical Annotation available VA No VIP available No VIP available
NAT2 and CYP2E1 polymorphisms and susceptibility to first-line anti-tuberculosis drug-induced hepatitis. The international journal of tuberculosis and lung disease : the official journal of the International Union against Tuberculosis and Lung Disease. 2010. Lee S-W, et al. PubMed
No Dosing Guideline available No Drug Label available No Clinical Annotation available VA No VIP available No VIP available
Low N-acetyltransferase 2 activity in isoniazid-associated acute hepatitis requiring liver transplantation. Transplant international : official journal of the European Society for Organ Transplantation. 2010. Cramer Jakob P, et al. PubMed
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available No VIP available No VIP available
Dose adjustment of the non-nucleoside reverse transcriptase inhibitors during concurrent rifampicin-containing tuberculosis therapy: one size does not fit all. Expert opinion on drug metabolism & toxicology. 2010. Kwara Awewura, et al. PubMed
No Dosing Guideline available No Drug Label available CA VA No VIP available No VIP available
GSTT1 and GSTM1 null mutations and adverse reactions induced by antituberculosis drugs in Koreans. Tuberculosis (Edinburgh, Scotland). 2010. Kim Sang-Heon, et al. PubMed
No Dosing Guideline available No Drug Label available CA VA No VIP available No VIP available
Genetic polymorphisms of cytochrome P450 and glutathione S-transferase associated with antituberculosis drug-induced hepatotoxicity in Chinese tuberculosis patients. The Journal of international medical research. 2010. Wang T, et al. PubMed
No Dosing Guideline available No Drug Label available No Clinical Annotation available VA No VIP available No VIP available
Genetic polymorphisms of drug-metabolizing enzymes and anti-TB drug-induced hepatitis. Pharmacogenomics. 2009. Kim Sang-Heon, et al. PubMed
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available No VIP available No VIP available
Warfarin interactions with substances listed in drug information compendia and in the FDA-approved label for warfarin sodium. Clinical pharmacology and therapeutics. 2009. Anthony M, et al. PubMed
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available No VIP available No VIP available
Is there a place for drug combination strategies using clinical pharmacology attributes?--review of current trends in research. Current clinical pharmacology. 2009. Srinivas Nuggehally R. PubMed
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available VIP No VIP available
Methadone induces the expression of hepatic drug-metabolizing enzymes through the activation of pregnane X receptor and constitutive androstane receptor. Drug metabolism and disposition: the biological fate of chemicals. 2009. Tolson Antonia H, et al. PubMed
No Dosing Guideline available No Drug Label available CA VA No VIP available No VIP available
Rifampicin alters atorvastatin plasma concentration on the basis of SLCO1B1 521T>C polymorphism. Clinica chimica acta; international journal of clinical chemistry. 2009. He Yi-Jing, et al. PubMed
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available VIP No VIP available
Relative impact of genotype and enzyme induction on the metabolic capacity of CYP2C9 in healthy volunteers. Clinical pharmacology and therapeutics. 2009. Vormfelde S V, et al. PubMed
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available VIP No VIP available
Histone deacetylase inhibitors induce a very broad, pleiotropic anticancer drug resistance phenotype in acute myeloid leukemia cells by modulation of multiple ABC transporter genes. Clinical cancer research : an official journal of the American Association for Cancer Research. 2009. Hauswald Stefanie, et al. PubMed
No Dosing Guideline available No Drug Label available CA No Variant Annotation available No VIP available No VIP available
The SLCO1B1*5 genetic variant is associated with statin-induced side effects. Journal of the American College of Cardiology. 2009. Voora Deepak, et al. PubMed
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available VIP No VIP available
Genetic determinants of response to clopidogrel and cardiovascular events. The New England journal of medicine. 2009. Simon Tabassome, et al. PubMed
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available No VIP available No VIP available
CYP2B6 (c.516G-->T) and CYP2A6 (*9B and/or *17) polymorphisms are independent predictors of efavirenz plasma concentrations in HIV-infected patients. British journal of clinical pharmacology. 2009. Kwara Awewura, et al. PubMed
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available VIP No VIP available
Redox regulation of multidrug resistance in cancer chemotherapy: molecular mechanisms and therapeutic opportunities. Antioxidants & redox signaling. 2009. Kuo Macus Tien. PubMed
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available No VIP available No VIP available
Sorafenib: a review of its use in advanced hepatocellular carcinoma. Drugs. 2009. Keating Gillian M, et al. PubMed
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available VIP No VIP available
Several major antiepileptic drugs are substrates for human P-glycoprotein. Neuropharmacology. 2008. Luna-Tortós Carlos, et al. PubMed
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available No VIP available No VIP available
Pharmacokinetics and pharmacodynamics of drug interactions involving rifampicin, rifabutin and antimalarial drugs. The Journal of antimicrobial chemotherapy. 2008. Sousa Marta, et al. PubMed
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available No VIP available No VIP available
Pharmacokinetics of efavirenz when co-administered with rifampin in TB/HIV co-infected patients: pharmacogenetic effect of CYP2B6 variation. Journal of clinical pharmacology. 2008. Kwara Awewura, et al. PubMed
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available VIP No VIP available
A comprehensive in vitro and in silico analysis of antibiotics that activate pregnane X receptor and induce CYP3A4 in liver and intestine. Drug metabolism and disposition: the biological fate of chemicals. 2008. Yasuda Kazuto, et al. PubMed
No Dosing Guideline available No Drug Label available No Clinical Annotation available VA No VIP available No VIP available
Association of slow N-acetyltransferase 2 profile and anti-TB drug-induced hepatotoxicity in patients from Southern Brazil. European journal of clinical pharmacology. 2008. Possuelo L G, et al. PubMed
No Dosing Guideline available No Drug Label available CA VA No VIP available No VIP available
Influence of glutathione S-transferase M1 and T1 homozygous null mutations on the risk of antituberculosis drug-induced hepatotoxicity in a Caucasian population. Liver international : official journal of the International Association for the Study of the Liver. 2008. Leiro Virginia, et al. PubMed
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available VIP No VIP available
Structure, function and regulation of P-glycoprotein and its clinical relevance in drug disposition. Xenobiotica; the fate of foreign compounds in biological systems. 2008. Zhou S-F. PubMed
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available No VIP available No VIP available
Xenobiotic transporters of the human organic anion transporting polypeptides (OATP) family. Xenobiotica; the fate of foreign compounds in biological systems. 2008. Hagenbuch B, et al. PubMed
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available No VIP available No VIP available
Cytochrome P450 induction by rifampicin in healthy subjects: determination using the Karolinska cocktail and the endogenous CYP3A4 marker 4beta-hydroxycholesterol. Clinical pharmacology and therapeutics. 2008. Kanebratt K P, et al. PubMed
No Dosing Guideline available No Drug Label available CA VA No VIP available No VIP available
Effects of N-acetyltransferase 2 (NAT2), CYP2E1 and Glutathione-S-transferase (GST) genotypes on the serum concentrations of isoniazid and metabolites in tuberculosis patients. The Journal of toxicological sciences. 2008. Fukino Katsumi, et al. PubMed
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available No VIP available No VIP available
Acquired rifamycin resistance: pharmacology and biology. Expert review of anti-infective therapy. 2008. Wallis Robert S, et al. PubMed
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available No VIP available No VIP available
Pharmacogenomics of anti-TB drugs-related hepatotoxicity. Pharmacogenomics. 2008. Roy Puspita Das, et al. PubMed
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available VIP No VIP available
Azole antimycotics differentially affect rifampicin-induced pregnane X receptor-mediated CYP3A4 gene expression. Drug metabolism and disposition: the biological fate of chemicals. 2008. Svecova Lucie, et al. PubMed
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available No VIP available No VIP available
Antituberculosis drug-induced hepatotoxicity: concise up-to-date review. Journal of gastroenterology and hepatology. 2008. Tostmann Alma, et al. PubMed
No Dosing Guideline available No Drug Label available CA VA No VIP available No VIP available
Novel single nucleotide polymorphisms in the promoter and intron 1 of human pregnane X receptor/NR1I2 and their association with CYP3A4 expression. Drug metabolism and disposition: the biological fate of chemicals. 2008. Lamba Jatinder, et al. PubMed
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available No VIP available No VIP available
Effect of rifampin, an inducer of CYP3A and P-glycoprotein, on the pharmacokinetics of risperidone. Journal of clinical pharmacology. 2008. Kim Kyoung-Ah, et al. PubMed
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available VIP No VIP available
Polymorphisms in the drug transporter gene ABCB1 predict antidepressant treatment response in depression. Neuron. 2008. Uhr Manfred, et al. PubMed
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available VIP No VIP available
Citalopram enantiomers in plasma and cerebrospinal fluid of ABCB1 genotyped depressive patients and clinical response: a pilot study. Pharmacological research : the official journal of the Italian Pharmacological Society. 2008. Nikisch Georg, et al. PubMed
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available No VIP available No VIP available
New anti-tuberculosis drugs with novel mechanisms of action. Current medicinal chemistry. 2008. Rivers Emma C, et al. PubMed
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available No VIP available No VIP available
Dexamethasone in Vietnamese adolescents and adults with bacterial meningitis. The New England journal of medicine. 2007. Nguyen Thi Hoang Mai, et al. PubMed
No Dosing Guideline available No Drug Label available No Clinical Annotation available VA No VIP available No VIP available
Determining the relation between N-acetyltransferase-2 acetylator phenotype and antituberculosis drug induced hepatitis by molecular biologic tests. Tüberküloz ve toraks. 2008. Bozok Cetintaş Vildan, et al. PubMed
No Dosing Guideline available No Drug Label available No Clinical Annotation available VA No VIP available No VIP available
NAT2 6A, a haplotype of the N-acetyltransferase 2 gene, is an important biomarker for risk of anti-tuberculosis drug-induced hepatotoxicity in Japanese patients with tuberculosis. World journal of gastroenterology : WJG. 2007. Higuchi Norihide, et al. PubMed
No Dosing Guideline available No Drug Label available No Clinical Annotation available VA No VIP available No VIP available
Genetic polymorphisms of NAT2 and CYP2E1 associated with antituberculosis drug-induced hepatotoxicity in Korean patients with pulmonary tuberculosis. Tuberculosis (Edinburgh, Scotland). 2007. Cho Hyun-Jung, et al. PubMed
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available VIP No VIP available
Polymorphic CYP2B6: molecular mechanisms and emerging clinical significance. Pharmacogenomics. 2007. Zanger Ulrich M, et al. PubMed
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available No VIP available No VIP available
Effects of uptake and efflux transporter inhibition on erythromycin breath test results. Clinical pharmacology and therapeutics. 2007. Frassetto L A, et al. PubMed
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available No VIP available No VIP available
Two years review of cutaneous adverse drug reaction from first line anti-tuberculous drugs. The Medical journal of Malaysia. 2007. Tan W C, et al. PubMed
No Dosing Guideline available No Drug Label available CA No Variant Annotation available No VIP available No VIP available
Different effects of SLCO1B1 polymorphism on the pharmacokinetics of atorvastatin and rosuvastatin. Clinical pharmacology and therapeutics. 2007. Pasanen M K, et al. PubMed
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available No VIP available No VIP available
effect of OATP1B transporter inhibition on the pharmacokinetics of atorvastatin in healthy volunteers. Clinical pharmacology and therapeutics. 2007. Lau Y Y, et al. PubMed
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available No VIP available No VIP available
Expression levels and activation of a PXR variant are directly related to drug resistance in osteosarcoma cell lines. Cancer. 2007. Mensah-Osman Edith J, et al. PubMed
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available No VIP available No VIP available
Inhibitory and inductive effects of rifampin on the pharmacokinetics of bosentan in healthy subjects. Clinical pharmacology and therapeutics. 2007. van Giersbergen P L M, et al. PubMed
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available No VIP available No VIP available
Relative activation of human pregnane X receptor versus constitutive androstane receptor defines distinct classes of CYP2B6 and CYP3A4 inducers. The Journal of pharmacology and experimental therapeutics. 2007. Faucette Stephanie R, et al. PubMed
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available VIP No VIP available
Cobalamin potentiates vinblastine cytotoxicity through downregulation of mdr-1 gene expression in HepG2 cells. Cellular physiology and biochemistry : international journal of experimental cellular physiology, biochemistry, and pharmacology. 2007. Marguerite Véronique, et al. PubMed
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available VIP No VIP available
Mechanism of inhibition of P-glycoprotein mediated efflux by vitamin E TPGS: influence on ATPase activity and membrane fluidity. Molecular pharmaceutics. 2007. Collnot Eva-Maria, et al. PubMed
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available No VIP available No VIP available
Disposition and sterol-lowering effect of ezetimibe are influenced by single-dose coadministration of rifampin, an inhibitor of multidrug transport proteins. Clinical pharmacology and therapeutics. 2006. Oswald Stefan, et al. PubMed
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available No VIP available No VIP available
Rifampin induces alterations in mycophenolic acid glucuronidation and elimination: implications for drug exposure in renal allograft recipients. Clinical pharmacology and therapeutics. 2006. Naesens Maarten, et al. PubMed
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available No VIP available No VIP available
Systematic screening for polymorphisms in the CYP3A4 gene in the Chinese population. Pharmacogenomics. 2006. Du Jing, et al. PubMed
No Dosing Guideline available No Drug Label available No Clinical Annotation available VA No VIP available No VIP available
DNA microarray genotyping of N-acetyltransferase 2 polymorphism using carbodiimide as the linker for assessment of isoniazid hepatotoxicity. Tuberculosis (Edinburgh, Scotland). 2006. Shimizu Yasuo, et al. PubMed
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available VIP No VIP available
Gefitinib modulates the function of multiple ATP-binding cassette transporters in vivo. Cancer research. 2006. Leggas Markos, et al. PubMed
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available VIP No VIP available
Comparison of midazolam and simvastatin as cytochrome P450 3A probes. Clinical pharmacology and therapeutics. 2006. Chung Ellen, et al. PubMed
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available VIP No VIP available
Impact of P-glycoprotein on clopidogrel absorption. Clinical pharmacology and therapeutics. 2006. Taubert Dirk, et al. PubMed
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available VIP No VIP available
Evaluation of 170 xenobiotics as transactivators of human pregnane X receptor (hPXR) and correlation to known CYP3A4 drug interactions. Current drug metabolism. 2006. Sinz Michael, et al. PubMed
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available No VIP available No VIP available
MDR1 genotype is associated with hepatic cytochrome P450 3A4 basal and induction phenotype. Clinical pharmacology and therapeutics. 2006. Lamba Jatinder, et al. PubMed
No Dosing Guideline available No Drug Label available No Clinical Annotation available VA No VIP available No VIP available
Predisposition of antituberculosis drug induced hepatotoxicity by cytochrome P450 2E1 genotype and haplotype in pediatric patients. Journal of gastroenterology and hepatology. 2006. Roy Bidyut, et al. PubMed
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available No VIP available No VIP available
Adverse reactions to first-line antituberculosis drugs. Expert opinion on drug safety. 2006. Forget Eric J, et al. PubMed
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available No VIP available No VIP available
Effect of rifampicin on the pharmacokinetics of pioglitazone. British journal of clinical pharmacology. 2006. Jaakkola Tiina, et al. PubMed
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available VIP No VIP available
Single nucleotide polymorphisms in human P-glycoprotein: its impact on drug delivery and disposition. Expert opinion on drug delivery. 2006. Dey Surajit. PubMed
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available No VIP available No VIP available
Idiosyncratic drug hepatotoxicity. Nature reviews. Drug discovery. 2005. Kaplowitz Neil. PubMed
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available No VIP available No VIP available
Possible involvement of pregnane X receptor-enhanced CYP24 expression in drug-induced osteomalacia. The Journal of clinical investigation. 2005. Pascussi Jean Marc, et al. PubMed
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available VIP No VIP available
Pharmacokinetic drug interactions of gefitinib with rifampicin, itraconazole and metoprolol. Clinical pharmacokinetics. 2005. Swaisland Helen C, et al. PubMed
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available No VIP available No VIP available
The induction of cytochrome P450 3A5 (CYP3A5) in the human liver and intestine is mediated by the xenobiotic sensors pregnane X receptor (PXR) and constitutively activated receptor (CAR). The Journal of biological chemistry. 2004. Burk Oliver, et al. PubMed
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available VIP No VIP available
Influence of lipid lowering fibrates on P-glycoprotein activity in vitro. Biochemical pharmacology. 2004. Ehrhardt Manuela, et al. PubMed
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available No VIP available No VIP available
Contribution of hepatic cytochrome P450 3A4 metabolic activity to the phenomenon of clopidogrel resistance. Circulation. 2004. Lau Wei C, et al. PubMed
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available VIP No VIP available
Interactions of human P-glycoprotein with simvastatin, simvastatin acid, and atorvastatin. Pharmaceutical research. 2004. Hochman Jerome H, et al. PubMed
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available VIP No VIP available
Polymorphisms in human MDR1 (P-glycoprotein): recent advances and clinical relevance. Clinical pharmacology and therapeutics. 2004. Marzolini Catia, et al. PubMed
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available No VIP available No VIP available
Effects of prototypical microsomal enzyme inducers on cytochrome P450 expression in cultured human hepatocytes. Drug metabolism and disposition: the biological fate of chemicals. 2003. Madan Ajay, et al. PubMed
No Dosing Guideline available No Drug Label available No Clinical Annotation available VA No VIP available No VIP available
Cytochrome P450 2E1 genotype and the susceptibility to antituberculosis drug-induced hepatitis. Hepatology (Baltimore, Md.). 2003. Huang Yi-Shin, et al. PubMed
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available No VIP available No VIP available
Human organic anion transporting polypeptide-C (SLC21A6) is a major determinant of rifampin-mediated pregnane X receptor activation. The Journal of pharmacology and experimental therapeutics. 2003. Tirona Rommel G, et al. PubMed
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available VIP No VIP available
Genetic polymorphisms of the human MDR1 drug transporter. Annual review of pharmacology and toxicology. 2003. Schwab Matthias, et al. PubMed
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available No VIP available No VIP available
Human extrahepatic cytochromes P450: function in xenobiotic metabolism and tissue-selective chemical toxicity in the respiratory and gastrointestinal tracts. Annual review of pharmacology and toxicology. 2003. Ding Xinxin, et al. PubMed
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available No VIP available No VIP available
Nuclear pregnane x receptor and constitutive androstane receptor regulate overlapping but distinct sets of genes involved in xenobiotic detoxification. Molecular pharmacology. 2002. Maglich Jodi M, et al. PubMed
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available VIP No VIP available
CYP3A4 induction by drugs: correlation between a pregnane X receptor reporter gene assay and CYP3A4 expression in human hepatocytes. Drug metabolism and disposition: the biological fate of chemicals. 2002. Luo Gang, et al. PubMed
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available No VIP available No VIP available
Interactions of rifamycin SV and rifampicin with organic anion uptake systems of human liver. Hepatology (Baltimore, Md.). 2002. Vavricka Stephan R, et al. PubMed
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available No VIP available No VIP available
A cell-based reporter gene assay for determining induction of CYP3A4 in a high-volume system. The Journal of pharmacology and experimental therapeutics. 2002. Raucy Judy, et al. PubMed
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available VIP No VIP available
Regulation of multidrug resistance-associated protein 2 (ABCC2) by the nuclear receptors pregnane X receptor, farnesoid X-activated receptor, and constitutive androstane receptor. The Journal of biological chemistry. 2002. Kast Heidi R, et al. PubMed
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available No VIP available No VIP available
Med-psych drug-drug interactions update. Psychosomatics. 2002. Armstrong Scott C, et al. PubMed
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available No VIP available No VIP available
Rifampin is a selective, pleiotropic inducer of drug metabolism genes in human hepatocytes: studies with cDNA and oligonucleotide expression arrays. The Journal of pharmacology and experimental therapeutics. 2001. Rae J M, et al. PubMed
No Dosing Guideline available No Drug Label available No Clinical Annotation available VA No VIP available No VIP available
The human pregnane X receptor: genomic structure and identification and functional characterization of natural allelic variants. Pharmacogenetics. 2001. Zhang J, et al. PubMed
No Dosing Guideline available No Drug Label available CA VA No VIP available No VIP available
Increased risk of antituberculosis drug-induced hepatotoxicity in individuals with glutathione S-transferase M1 'null' mutation. Journal of gastroenterology and hepatology. 2001. Roy B, et al. PubMed
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available No VIP available No VIP available
Peptide mimetic HIV protease inhibitors are ligands for the orphan receptor SXR. The Journal of biological chemistry. 2001. Dussault I, et al. PubMed
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available VIP No VIP available
The orphan nuclear receptor SXR coordinately regulates drug metabolism and efflux. Nature medicine. 2001. Synold T W, et al. PubMed
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available VIP No VIP available
Interaction of omeprazole, lansoprazole and pantoprazole with P-glycoprotein. Naunyn-Schmiedeberg's archives of pharmacology. 2001. Pauli-Magnus C, et al. PubMed
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available VIP No VIP available
Nuclear receptor response elements mediate induction of intestinal MDR1 by rifampin. The Journal of biological chemistry. 2001. Geick A, et al. PubMed
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available VIP No VIP available
Up-regulation of transporters of the MRP family by drugs and toxins. Toxicology letters. 2001. Schrenk D, et al. PubMed
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available No VIP available No VIP available
Clinical pharmacokinetics of fluvastatin. Clinical pharmacokinetics. 2001. Scripture C D, et al. PubMed
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available No VIP available No VIP available
CYP2A5/CYP2A6 expression in mouse and human hepatocytes treated with various in vivo inducers. Drug metabolism and disposition: the biological fate of chemicals. 2000. Donato M T, et al. PubMed
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available No VIP available No VIP available
Humanized xenobiotic response in mice expressing nuclear receptor SXR. Nature. 2000. Xie W, et al. PubMed
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available VIP No VIP available
Rifampin greatly reduces plasma simvastatin and simvastatin acid concentrations. Clinical pharmacology and therapeutics. 2000. Kyrklund C, et al. PubMed
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available VIP No VIP available
Orphan nuclear receptors constitutive androstane receptor and pregnane X receptor share xenobiotic and steroid ligands. The Journal of biological chemistry. 2000. Moore L B, et al. PubMed
No Dosing Guideline available No Drug Label available No Clinical Annotation available VA No VIP available No VIP available
Slow N-acetyltransferase 2 genotype affects the incidence of isoniazid and rifampicin-induced hepatotoxicity. The international journal of tuberculosis and lung disease : the official journal of the International Union against Tuberculosis and Lung Disease. 2000. Ohno M, et al. PubMed
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available VIP No VIP available
The pregnane X receptor: a promiscuous xenobiotic receptor that has diverged during evolution. Molecular endocrinology (Baltimore, Md.). 2000. Jones S A, et al. PubMed
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available VIP No VIP available
The role of intestinal P-glycoprotein in the interaction of digoxin and rifampin. The Journal of clinical investigation. 1999. Greiner B, et al. PubMed
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available VIP No VIP available
Biochemical, cellular, and pharmacological aspects of the multidrug transporter. Annual review of pharmacology and toxicology. 1999. Ambudkar S V, et al. PubMed
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available VIP No VIP available
Identification of a human nuclear receptor defines a new signaling pathway for CYP3A induction. Proceedings of the National Academy of Sciences of the United States of America. 1998. Bertilsson G, et al. PubMed
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available VIP No VIP available
The human orphan nuclear receptor PXR is activated by compounds that regulate CYP3A4 gene expression and cause drug interactions. The Journal of clinical investigation. 1998. Lehmann J M, et al. PubMed
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available VIP No VIP available
Effects of erythromycin or rifampin on losartan pharmacokinetics in healthy volunteers. Clinical pharmacology and therapeutics. 1998. Williamson K M, et al. PubMed
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available VIP No VIP available
Competitive, non-competitive and cooperative interactions between substrates of P-glycoprotein as measured by its ATPase activity. Biochimica et biophysica acta. 1997. Litman T, et al. PubMed
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available VIP No VIP available
Enhanced cyclophosphamide and ifosfamide activation in primary human hepatocyte cultures: response to cytochrome P-450 inducers and autoinduction by oxazaphosphorines. Cancer research. 1997. Chang T K, et al. PubMed
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available No VIP available No VIP available
Pharmacogenetic determinants of codeine induction by rifampin: the impact on codeine's respiratory, psychomotor and miotic effects. The Journal of pharmacology and experimental therapeutics. 1997. Caraco Y, et al. PubMed
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available VIP No VIP available
P-glycoprotein structure and evolutionary homologies. Cytotechnology. 1993. Croop J M. PubMed
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available VIP No VIP available
Induction of polymorphic 4'-hydroxylation of S-mephenytoin by rifampicin. British journal of clinical pharmacology. 1990. Zhou H H, et al. PubMed

LinkOuts

Web Resource:
Wikipedia
National Drug Code Directory:
0904-5282-06
DrugBank:
DB01045
ChEBI:
28077
KEGG Compound:
C06688
KEGG Drug:
D00211
PubChem Compound:
5381226
PubChem Substance:
168608
Drugs Product Database (DPD):
393444
Therapeutic Targets Database:
DNC000965
FDA Drug Label at DailyMed:
0a99a222-580b-4d80-8aaf-1c74d9a6caab

Clinical Trials

These are trials that mention rifampin and are related to either pharmacogenetics or pharmacogenomics.

Common Searches

Search PubMed
Search Medline Plus
Search PubChem
Search CTD

Sources for PharmGKB drug information: DrugBank, Open Eye Scientific Software.